RESEARCH ARTICLE
Gout Transitions from Medieval Times into the 21st Century
Puja P. Khanna*
Article Information
Identifiers and Pagination:
Year: 2016Volume: 9
Issue: Suppl 1: M4
First Page: 22
Last Page: 26
Publisher ID: TOUNJ-9-22
DOI: 10.2174/1874303X01609010022
Article History:
Received Date: 18/4/2015Revision Received Date: 30/4/2015
Acceptance Date: 30/4/2015
Electronic publication date: 11/02/2016
Collection year: 2016

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Gout is the most treatable arthritis in the Western World—the pathophysiology of which is related to uric acid metabolism and there are effective medications available to treat both acute arthritis and chronic hyperuricemia. Despite this many patients continue to suffer from tophaceous gout with major detrimental effects on patient-reported outcomes and substantial economic impact. Poor adherence to medications is considered an important attribute in developing disability due to gout. This review summarizes recommendations from various national and international guidelines with an update on the therapeutics.
Key Points
- NSAIDs, COX-2 inhibitors, corticosteroids, colchicine, and IL-1 inhibitors have strong evidence to suggest efficacy in the treatment of acute gout.
- Urate lowering therapy, with allopurinol or febuxostat as first line agents, is warranted for chronic management of gout.
- All guidelines recommend a ‘treat-to-target’ strategy to achieve serum urate of at least 6 mg/dL or lower.